New Reference: SOX for Gastric/GEJ AdenoCa

Open-label, randomized, phase 3 trial (RESOLVE)

Patients with cT4a N+ M0 or cT4b Nany M0 gastric or gastro-oesophageal junction adenocarcinoma after D2 gastrectomy

Perioperative SOX vs. Adjuvant SOX vs. Adjuvant CapOx

5-yr OS: 60.0% vs. 61.0% vs. 52.1% (peri-SOX vs. adjuvant-SOX vs. adjuvant-CapOx)

mOS: NR vs. NR vs. NR

OS HR: 0.79 [0.62-1.00] (peri-SOX vs. adjuvant-CapOx)

OS HR: 0.77 [0.61-0.98] (adjuvant-SOX vs. adjuvant-CapOx)

5-yr DFS: 53.2% vs. 50.8% vs. 45.8%

DFS HR: 0.79 [0.63-0.98] (peri-SOX vs. adjuvant-CapOx)

DFS HR: 0.86 [0.69-1.06] (adjuvant-SOX vs. adjuvant-CapOx)

Safety data not updated in this report

Zhang X,Liang H,Li Z Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial

Reviewed by Ulas D. Bayraktar, MD on Apr 7, 2025